




LinkedIn

State-of-the-art Bi/Multi-specific Antibody Cell Line Development Platform

AlfaCell

Site specific integration





7 days: short post transfection time



6 weeks for cell line development




Bypasses the mini pool and limited dilution for monoclonal cell



>5 g/L and >80% correct paring: for Bi/Multi-specific antibody production


Best Design


"411" Strategy: FOUR chains in ONE vector and integrated into ONE hot spot



Identify Quality in Advance

Screening from the cell pool for high titer and quality candidates In SSI platform: Same quality attributes in cell pool and monoclones





Case Study

Achieve high titer and high quality for all kinds of bispecific

| Structure | Clients | MW (KDa) | AlfaCell Titer (g/L) | Random Titer (g/L) | Correct Paring% |
|---------------------------------------|----------|-------------|-------------------------|-----------------------|-----------------|
| Mab-scFv | 2 chains | 200 | 2.5 | 1.8 | 96% |
| No. No. | 2 chains | 200 | 5.5 | - | 68% |
| VL1 VH1 VL2 VH2 CL CH CH2 CH3 CH3 | 2 chains | 124 | 12.0 | 3.6 | 54.6% |
| Target VH2 VL (G4S)3 Ingel VI IgG1 | 2 chains | 250 | 0.8 | 0.06 | 98% |
| TAA CD3 | 3 chains | 130 | 5.5 | | 90% |
| CH1 CL VL CH1 CH2 CH2 CH3 | 4 chains | 150 | 6 | - | 87% |